CRISPR

CRISPR1-mc1r

ID
ZDB-CRISPR-200528-3
Name
CRISPR1-mc1r
Previous Names
None
Target
Sequence
5' - GCTAGTGAGCGTCAGTAATG - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
The PAM site was "TGG" at the 3' end.
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
iim17 mc1r
Expression
Gene expression in Wild Types + CRISPR1-mc1r
No data available
Phenotype
Phenotype resulting from CRISPR1-mc1r
No data available
Phenotype of all Fish created by or utilizing CRISPR1-mc1r
Phenotype Fish Conditions Figures
head kidney c3a.2 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
head melanocyte decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 3 from Cal et al., 2019
head kidney il10 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
spleen ight expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
brain il1b expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
brain ptgs2a expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
head kidney il10 expression decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
integument tnfa expression decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
head kidney ptgs2a expression decreased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
spleen tnfa expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
integument ifng1 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
spleen il6 expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
head kidney il1b expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
brain ight expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
brain lyz expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
head kidney c3a.2 expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 5 from Fierro-Castro et al., 2022
head kidney il6 expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
integument nos2a expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
spleen il1b expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
head kidney ight expression decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 5 from Fierro-Castro et al., 2022
spleen ight expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 5 from Fierro-Castro et al., 2022
integument c3a.2 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
spleen c3a.2 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
head kidney tnfa expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
dorsal larval melanophore stripe melanocyte decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 3 from Cal et al., 2019
spleen ptgs2a expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
spleen lyz expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
spleen nfkb2 expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
ventral larval melanophore stripe melanocyte decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 3 from Cal et al., 2019
head kidney ptgs2a expression decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
integument ighm expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 5 from Fierro-Castro et al., 2022
integument ighm expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
brain il10 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
brain il10 expression decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
integument il6 expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
integument tnfa expression decreased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
monocyte amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 3 from Fierro-Castro et al., 2022
spleen tnfa expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
integument il10 expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
integument il10 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
brain ighm expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
brain il6 expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
head kidney ight expression decreased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
integument ight expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
spleen il10 expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
spleen ptgs2a expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
head kidney ighm expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
head kidney lyz expression amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
lateral larval melanophore stripe melanocyte decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 3 from Cal et al., 2019
integument cortisol increased amount, ameliorated mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 1 from Fierro-Castro et al., 2022
spleen il10 expression increased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
trunk melanocyte decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 3 from Cal et al., 2019
brain nos2a expression decreased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 4 from Fierro-Castro et al., 2022
brain c3a.2 expression decreased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 5 from Fierro-Castro et al., 2022
integument nos2a expression decreased amount, abnormal mc1riim17/iim17 (TU) chemical treatment by injection: lipopolysaccharide Fig. 4 from Fierro-Castro et al., 2022
spleen lyz expression increased amount, abnormal mc1riim17/iim17 (TU) standard conditions Fig. 5 from Fierro-Castro et al., 2022
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.